|UCB agrees to buy Ra Pharma for $2.5B|
Oct. 10, 2019 6:51 AM ET|About: UCB SA (UCBJF)|By: Douglas W. House, SA News Editor
UCB SA ( OTCPK:UCBJF) has agreed to acquire Ra Pharmaceuticals (NASDAQ: RARX) for $48 per share in cash or $2.5B (€2.2B)($2.1B net of RARX cash).
UCB says the deal is consistent with its "Accelerate and Expand" strategy. In this case, it gains access to RA's zilucoplan, in Phase 3 development for myasthenia gravis (MG), complementing its own rozanolixizumab, also in late-stage development for MG.
Zilucoplan is also being evaluated in other complement-mediated disorders like ALS and immune-mediated necrotizing myopathy.
The transaction will not affect UCB's 2019 financial guidance. It will be dilutive to its mid-term earnings and will extend its mid-term goal of EBITDA/revenue of 31% out one year to 2022.
The deal should close by the end of Q1 2020.
RARX is up 106% premarket on light volume.